Having read the consensus statement and all the papers from the Milan conference (available without subscription), I prepared my version of this for the Antwerp conference. This talk contained the following:
- A description of why the Westgard model for total error is incomplete (with of course Jim Westgard sitting in the audience)
- A description of why expanded total error models are nevertheless also incomplete
- A critique of Boyd and Bruns’ glucose meter performance simulations using the Westgard model
- A critique of the ISO and CLSI glucose meter specifications, both based on total error
- A description of what the companies with most of the market share in glucose meters did, when they started to lose market share
- How Ciba Corning specified and evaluated performance
- What I currently recommend
I submitted a written version of this talk to Clin Chem and Lab Medicine, with recommended reviewers being Milan authors with whom I disagreed. (The journal asks authors to recommend reviewers). Now I don’t know who the reviewers were, but suffice it to say that they didn’t like my paper at all. So after several revisions, I scaled back my paper to its current version, which is here (subscription required).